QR-Code

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

Abstract Background Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the low to moderate quality of the generated evidence, safety concerns and restricted pr...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2025-01-01
Schriftenreihe:Cardio-Oncology
Schlagworte:
Diffuse large B-Cell lymphoma
R-CHOP chemotherapy
Anthracyclines
Dexrazoxane
Cardiotoxicity
Randomized Controlled Trial
Online-Zugang:https://doi.org/10.1186/s40959-025-00303-y
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge